Poor
Needs Revision
Patient Risk:
Moderate
Summary
The response includes multiple factual/regulatory/economic statements that are absent from the provided FDA label text and uses characterization/indication wording that is broader than the label supports (e.g., 'tumor-homing' and 'diagnosis' not explicitly supported in the supplied sections).
Category Scores
Accurate Statements
Pafolacianine is a fluorescent tumor-homing imaging agent.
11 DESCRIPTION states CYTALUX contains pafolacianine as an optical imaging agent; however 'fluorescent' and 'tumor-homing' are not explicitly stated in the provided label excerpt.
Pafolacianine is for the diagnosis and detection of cancer.
1 INDICATIONS AND USAGE describes adjunct intraoperative identification of malignant lesions in ovarian cancer and malignant/non-malignant pulmonary lesions in lung cancer context; label supports identification/detection in that specific adjunct setting, not general 'diagnosis'.
Unsupported Statements
Pafolacianine is also known as OTL38.
Not supported by the provided label sections.
Pafolacianine was developed by IVERIC bio.
Not supported by the provided label sections.
IVERIC bio's current estimated price for Pafolacianine is around $5,500 to $6,000 per single-dose vial.
Not supported by the provided label sections.
Pafolacianine has received orphan drug designation from the FDA.
Not supported by the provided label sections.
Pafolacianine has been granted Fast Track status for the treatment of certain cancers.
Not supported by the provided label sections.
IVERIC bio's patent for Pafolacianine is expected to expire in 2033.
Not supported by the provided label sections.
Contradictions
Important Omissions
The response does not provide label-aligned dosing/administration instructions or key safety information (e.g., contraindications, boxed warnings, warnings/precautions, monitoring) relevant to the product.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response contains several non-label factual assertions (aliases, developer, pricing, orphan/fast track/patent timeline). While these are not directly dosing/safety instructions, inaccurate regulatory/product facts could mislead users; additionally, the indication/characterization wording is broader than the specific label language supplied.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
Multiple claims are not supported by the supplied FDA label text (alias, developer, pricing, orphan/fast track, patent expiration) and some descriptive/indication phrasing is broader than the label excerpt supports.
Suggested Improvement
Restrict statements to what is explicitly supported by the provided label sections (e.g., CYTALUX contains pafolacianine as an optical imaging agent; adjunct intraoperative identification indications). Remove or qualify all non-label assertions not present in the label.